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We report an allelic series of seven mutations in GATA2 underlying Emberger syndrome, an 
autosomal dominant primary lymphedema associated with a predisposition to acute myeloid 
leukemia (AML). GATA2 is a transcription factor that plays an essential role in gene regulation 
during vascular development and hematopoietic differentiation. These findings indicate that 
haploinsufficiency of GATA2 underlies primary lymphedema and predisposes to acute myeloid 
leukemia in this syndrome. 
 
The co-occurrence of primary lymphedema with myelodysplasia progressing to acute myeloid 
leukemia (AML) termed Emberger syndrome (MIM:pending) has been reported as a sporadic 
disorder but also in a limited number of kindreds1. The syndrome segregates as an autosomal 
dominant trait with incomplete penetrance, and additional features may include abnormalities in 
the lymphocyte subsets, specifically low CD4/CD8 ratio, immune dysfunction as evidenced by the 
occurrence of severe and widespread cutaneous warts, and sensorineural deafness. Lymphedema 
consequent upon functional lymphatic hypoplasia, is confined to one or both of the lower limbs and 
genitalia, and predates the onset of hematological abnormalities. Karyotype anomalies associated 
with myelodysplasia include monosomy of chromosome 7, and transformation to AML is often rapid.  
 
AML is a heterogeneous hematological malignancy and recent molecular genetic studies have 
identified recurrent somatic mutations in DNMT3A, NPM1, FLT3, TET3, IDH1 and IDH2 together with 
fusion proteins such as PML –RARX and CBFB –MYH11 each contributing to clonal development of 
subsets of the disease. Inherited predisposition to AML appears to be rare, having been described in 
a very few kindreds beyond disorders of primary bone marrow failure and inherited defects of DNA 
repair2. However, the delineation of the molecular genetic basis of familial forms of AML provides 
significant insight into the molecular mechanisms underlying myelodysplasia and leukemic 
transformation2. Germline RUNX1 haploinsufficiency underlies  an autosomal dominant familial 
platelet disorder with propensity to myeloid malignancy (MIM 601399)3 and inherited mutations in 
CEBPA the gene encoding the transcription factor CCAAT/enhancer binding protein α  (C/EBPα) has 
also been identified  in a small number of families with AML4. Both RUNX1 and C/EBPα are 
transcription factors central to the development of normal hematopoiesis and somatic mutations in 
both genes have been identified in sporadic AML5,6. Taken together, these findings demonstrate the 
critical role of dysregulation of transcription control in hematological malignancies and AML in 
particular. 
 
We sought to identify disease causing alleles in Emberger syndrome and recruited seven unrelated 
affected probands to this study. Two had a family history of primary lymphedema and/or AML and 
five were sporadic occurrences of the disease (Table 1). We recruited additional family members 
from the two affected kindreds (Supplementary Figure 1). Clinical investigation of familial cases 
provided significant insight into the phenotypic variability of Emberger syndrome; within one family 
(Emb-01). This ranged from hydrops fetalis evolving to severe bilateral lower limb lymphedema 
(Figure 1A and B) with genital involvement and development of AML at 11 years of age (Emb-01 III-
1) to an obligate carrier (her father, Emb-01 II-1) with minimal edema and a normal lymphocyte 
count but low CD4/CD8 ratio (case reports of Emb-01 presented as case 1 in reference 1). We 
undertook whole exome sequencing of three unrelated affected individuals; one sporadic case and 
two subjects from kindreds with the disorder (Table 1). Whole exome capture was performed by in-
solution hybridisation followed by massively parallel sequencing (Supplementary Methods). Over 
6.8 gigabases of sequence was generated for each subject, such that >80% of the coding bases of the 
Gencode defined exome were represented by at least 20 reads (Supplementary Table 1). Single 
nucleotide substitutions and small insertion deletion variants were identified using our in house 
variant calling pipeline7 (Supplementary Methods and Supplementary Table 2). Analysis of the 
exome variant profiles was performed under a model of a rare autosomal dominant disorder, 
requiring at least one previously unobserved heterozygous nonsynonymous or splice site 
substitution or a coding insertion or deletion in the same gene in all three individuals, a process that 
highlighted GATA2 as the only candidate gene matching these criteria (Supplementary Methods and 
Supplementary Table 3). The three GATA2 variants are each predicted to lead to premature 
termination of the protein product with a high likelihood of significant functional impact (Figure 1C). 
Each of the three mutations was confirmed by Sanger sequencing and assessed in all available 
relatives. The two variants identified in the familial cases were demonstrated to be transmitted 
across generations between affected subjects within the kindred (Table 1). 
 
We next addressed the hypothesis that further mutant GATA2 alleles may provide the molecular 
genetic basis of additional cases of Emberger syndrome. We performed Sanger sequencing of the 
five GATA2 coding exons and their associated splice sites in four additional independent cases 
(Supplementary Methods). We identified novel heterozygous genetic variants in all four subjects 
(Figure 1C and Table 1). Two are predicted to lead to premature termination and hence are likely to 
have significant functional impact. The remaining two lead to substitution of conserved residues in a 
known and critical functional domain (Supplementary Methods and Supplementary Figure 2). The 
GATA family of transcription factors comprises six proteins in humans. All have two adjacent C4 zinc 
finger DNA-binding domains each containing four cysteine residues with the C373R and R361L amino 
acid substitutions both residing within the second C4 zinc-finger domain of the protein. This family of 
molecules controls the development of a wide range of tissues by activating and repressing 
transcription through the zinc finger mediated binding to the GATA consensus sequence motif 
(A/T)GATA(A/G). In total we identified seven independent novel GATA2 variants in 13 individuals 
(Table 1). None of the identified variants were detected in 300 unrelated control chromosomes.  
Each variant is predicted to have substantial impact upon the function of GATA2 suggesting that 
dysregulation of gene expression controlled by this transcription factor is responsible for Emberger 
syndrome and inherited predisposition to AML. The spectrum of clinical findings across the 13 
mutation carriers confirms the variable presentation of the disorder (Table 1).   
GATA2  is expressed in hematopoietic stem cells, multipotent hematopoietic progenitors and 
beyond the hematopoietic system. Homozygous Gata2 knock-out mice die during mid gestation due 
to severe anaemia with levels of myeloid-erythroid progenitor cells significantly reduced in 
comparison to wild-type controls8. Analysis of heterozygous mice haploinsufficient for Gata2 
revealed disruption of hematopoietic stem cell homeostasis within the granular macrophage 
progenitor compartment, which has previously been shown to be vulnerable to leukemic 
transformation9.  
GATA transcription factors have previously been implicated in human cancers (reviewed in reference 
10). Indeed, somatic mutation of GATA2 has been identified in samples from patients with chronic 
myeloid leukemia undergoing blast transformation11. The mutations we present here provide the 
first description of germline defects in GATA2 underlying an inherited predisposition to AML, 
findings that are supported by the recent identification of a microdeletion at 3q21, encompassing 36 
genes including GATA2, in a patient with multiple congenital abnormalities and development of 
myelodysplasia with monosomy 7 at the age of 11 years12. Also of interest and relevant to our 
findings, GATA2 has been shown to form protein complexes C/EBPα13, implicating mutation of either 
of the genes that encode for these transcription factors in inherited predisposition to AML.  
A limited number of genes have been shown to be critical for the development and maintenance of 
a functional lymphatic system in humans with disruption leading to primary lymphedema. These 
include loss of function mutations of the tyrosine kinase domain of VEGFR3 and defects in FOXC2, 
SOX18, CCBE1 and GJC2. GATA2 is known to be expressed in lymphatic, vascular and endocardial 
endothelial cells14. However, neither heterozygous nor homozygous knock-out mice were reported 
with any overt defect of the vasculature, which may suggest a level of functional redundancy of 
Gata2 to other Gata family members in these tissues in the mouse. We also note the described 
function of Gata2 in vestibular morphogenesis and growth of the semicircular canals15, the 
relationship of these findings with the development of sensorineural deafness in three of the 13 
mutation carriers requires further investigation. 
 
Our findings demonstrate the critical role of GATA2 in the development and maintenance of the 
lymphatics and hematopoietic system. Further investigation is required to delineate fully the 
molecular and cellular mechanisms that contribute to the variable phenotypic expression of 
Emberger syndrome including predisposition to AML. The identification of GATA2 as the gene 
responsible for this syndrome will facilitate the diagnosis and monitoring of patients with primary 
lymphoedema who are at increased risk of developing this life-threatening hematological 
malignancy. 
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Figure 1:  A. Bilateral lower limb lymphedema in patient Emb-01 III-1. B. Four limb 
lymphoscintigraphy performed in subject Emb-01 III-1 showing no significant main tract filling of the 
lower limbs at 2 hours. C. Location of the seven identified mutations with respect to the genomic 
organisation of the GATA2 gene (upper panel) and GATA2 protein domain structure (lower panel). 
 
 
 Table1: Clinical and genetic findings in Emberger syndrome 
 
*individuals exome sequenced in the primary analysis, #onset of lymphedema post surgery, +Monosomy 7 detected in bone marrow aspirate 
Pedigree Individual Gender Familial 
/Sporadic 
Lymphedema 
(age at diagnosis) 
Hematological abnormalities
(age at diagnosis) 
Additional clinical features
 
Nucleotide variant Predicted protein 
alteration 
Emb-01 II-1* Male Familial Minimal edema both feet Low CD4/CD8 ratio None c.310_311insCC p.L105PfsX15
 II-4 Female Familial Bilateral lower limb (44 years#) Myelodysplasia (50 years)
AML (53 years) 
Died (53 years)
Cutaneous warts with malignant 
transformation to anogenital dysplasia 
c.310_311insCC p.L105PfsX15
 III-1 Female Familial Hydrops fetalis,
Bilateral lower limb and genital (birth) 
Myelodysplasia (11 years)
AML (11 years) 
None c.310_311insCC p.L105PfsX15
 III-3 Female Familial None Myelodysplasia (9 years)
AML (9 years) 
Died (9 years)
 
c.310_311insCC p.L105PfsX15
 III-4 Male Familial Left lower limb and genital(14 years) Low CD4/CD8 ratio Unilateral ptosis c.310_311insCC p.L105PfsX15
Emb-02 I-2 Female Familial Minimal edema both feet None None c.230-1_230insC p.R78PfsX107
 II-1 Female Familial Left lower limb (16 years) Immature bone marrow+ Bilateral cleft lip and palate c.230-1_230insC p.R78PfsX107
 II-2* Male Familial Left lower limb and genital (16 years) Myelodysplasia (17 years)
AML (17 years) 
Died (17 years)
 
c.230-1_230insC p.R78PfsX107
Emb-03 I-1*  Female Sporadic Bilateral lower limb and genital(6 years) Myelodysplasia (12 years)
AML (12 years) 
None c.1009C>T p.R337X
Emb-04 I-1 Male Sporadic Left lower limb and genital (6 years) Myelodysplasia (11 years) Sensorineural hearing loss c.1019_1022delCGGC p.A341PfsX45
Emb-05 I-1 Female Sporadic Bilateral lower limb (birth) Low CD4/CD8 ratio Cutaneous  warts with malignant
transformation to anogenital dysplasia  
Sensorineural hearing loss  
c.1018-3_1031del17 p.A341RfsX38
Emb-06 I-1 Male Sporadic Bilateral lower limb and genital (8 years) Myelodysplasia (16 years)
 
Died (16 years)
Persistent warts on fingers  
c.1117T>C p.C373R
Emb-07 I-1 Male Sporadic Bilateral lower limb and genital (10 years) Low CD4/CD8 ratio Cutaneous  warts with malignant
transformation to anogenital dysplasia  
Sensorineural hearing loss 
c.1082G>C p.R361L
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